Alan J. Korman

50.9k total citations · 13 hit papers
113 papers, 15.6k citations indexed

About

Alan J. Korman is a scholar working on Immunology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Alan J. Korman has authored 113 papers receiving a total of 15.6k indexed citations (citations by other indexed papers that have themselves been cited), including 93 papers in Immunology, 80 papers in Oncology and 21 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Alan J. Korman's work include Cancer Immunotherapy and Biomarkers (68 papers), Immunotherapy and Immune Responses (50 papers) and Immune Cell Function and Interaction (39 papers). Alan J. Korman is often cited by papers focused on Cancer Immunotherapy and Biomarkers (68 papers), Immunotherapy and Immune Responses (50 papers) and Immune Cell Function and Interaction (39 papers). Alan J. Korman collaborates with scholars based in United States, Germany and Netherlands. Alan J. Korman's co-authors include James P. Allison, Karl S. Peggs, Jack L. Strominger, Mark Selby, Sergio A. Quezada, Changyu Wang, Jim Kaufman, Nils Lönberg, Tseng-hui Timothy Chen and John Engelhardt and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

In The Last Decade

Alan J. Korman

112 papers receiving 15.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

2010 2.3k citations Changyu Wang, Mark Selby et al. profile →
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

2003 778 citations Alan J. Korman, James P. Allison et al. profile →
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies

2009 726 citations Karl S. Peggs, Sergio A. Quezada et al. The Journal of Experimental Medicine profile →
Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells

2013 670 citations M. J. Selby, John Engelhardt et al. Cancer Immunology Research profile →
TIGIT and PD-1 impair tumor antigen–specific CD8+ T cells in melanoma patients

2015 608 citations Joë-Marc Chauvin, Ornella Pagliano et al. profile →
The class II molecules of the human and murine major histocompatibility complex

1984 557 citations Alan J. Korman et al. profile →
Evolving synergistic combinations of targeted immunotherapies to combat cancer

2015 498 citations Ignacio Melero, M. Ángela Aznar et al. profile →
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

2008 488 citations Alan J. Korman, James P. Allison et al. profile →
In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates

2014 472 citations Changyu Wang, Kent Thudium et al. Cancer Immunology Research profile →
Checkpoint Blockade in Cancer Immunotherapy

2006 463 citations Alan J. Korman, Karl S. Peggs et al. profile →
The foundations of immune checkpoint blockade and the ipilimumab approval decennial

2021 374 citations Alan J. Korman et al. profile →
Principles and use of anti-CTLA4 antibody in human cancer immunotherapy

2006 337 citations Karl S. Peggs, Sergio A. Quezada et al. profile →
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma

2013 233 citations James P. Allison, Walter J. Urba et al. profile →

Peers

Countries citing papers authored by Alan J. Korman

Since Specialization

Citations

This map shows the geographic impact of Alan J. Korman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan J. Korman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan J. Korman more than expected).

Fields of papers citing papers by Alan J. Korman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan J. Korman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan J. Korman. The network helps show where Alan J. Korman may publish in the future.

Co-authorship network of co-authors of Alan J. Korman

This figure shows the co-authorship network connecting the top 25 collaborators of Alan J. Korman. A scholar is included among the top collaborators of Alan J. Korman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alan J. Korman. Alan J. Korman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A novel small molecule Enpp1 inhibitor improves tumor control following radiation therapy by targeting stromal Enpp1 expression 2024 ·Scientific Reports ·Jason R. Baird, Alejandro Alice, Ryoichi Saito, (unknown), Minhua Han, (unknown), Sumin Han, (unknown), (unknown), Johannes Grosse, Alan J. Korman, (unknown), Venkatesh Rajamanickam, Brady Bernard, Marka R. Crittenden, Michael J. Gough	1
2	Preclinical Characterization of Relatlimab, a Human LAG-3–Blocking Antibody, Alone or in Combination with Nivolumab 2022 ·Cancer Immunology Research ·Kent Thudium, Mark Selby, Julie A. Zorn, Gregory D. Rak, (unknown), Roderick T. Bunch, Jason M. Hogan, Pavel Strop, Alan J. Korman	55
3	Fc-Optimized Anti-CCR8 Antibody Depletes Regulatory T Cells in Human Tumor Models 2021 ·Cancer Research ·(unknown), Bryan McDonald, (unknown), Nathan O. Siemers, (unknown), Mark Selby, Tim W. Sproul, Alan J. Korman, (unknown), (unknown), Sharmila Sambanthamoorthy, Kai Lǚ, (unknown), (unknown), Renu Jain, Ruth Y. Lan	76
4	IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma 2020 ·Clinical Cancer Research ·Joë-Marc Chauvin, Mignane Ka, Ornella Pagliano, Carmine Menna, Quanquan Ding, Richelle DeBlasio, Cindy Sander, Jiajie Hou, Xian-Yang Li, Soldano Ferrone, Diwakar Davar, John M. Kirkwood, Robert J. Johnston, Alan J. Korman, Mark J. Smyth, Hassane M. Zarour	114
5	TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer 2020 ·OncoImmunology ·(unknown), Janneke S. Hoogstad‐van Evert, (unknown), (unknown), (unknown), Alan J. Korman, Paul K.J.D. de Jonge, Jeannette Cany, Rob Woestenenk, Nicolaas Schaap, Leon F.A.G. Massuger, Joop H. Jansen, Willemijn Hobo, Harry Dolstra	54
6	Myeloid Cells Orchestrate Systemic Immunosuppression, Impairing the Efficacy of Immunotherapy against HPV+ Cancers 2019 ·Cancer Immunology Research ·(unknown), Stephan Wullschleger, Mélanie Tichet, Dhaarini Murugan, Nadine Zangger, Wesley Horton, Alan J. Korman, Lisa M. Coussens, Melody A. Swartz, Douglas Hanahan	28
7	CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function 2019 ·Cancer Immunology Research ·Deepak Mittal, Ailin Lepletier, Jason Madore, Amelia Roman Aguilera, Kimberley Stannard, Stephen J. Blake, Vicki Whitehall, Cheng Liu, Mark Bettington, Kazuyoshi Takeda, Georgina V. Long, Richard A. Scolyer, Ruth Y. Lan, Nathan O. Siemers, Alan J. Korman, Michele W.L. Teng, Robert J. Johnston, William C. Dougall, Mark J. Smyth	90
8	Tumor-Specific Inhibition of In Situ Vaccination by Distant Untreated Tumor Sites 2018 ·Cancer Immunology Research ·Zachary S. Morris, (unknown), Lauryn R. Werner, Peter M. Carlson, (unknown), Jasdeep S. Kler, (unknown), (unknown), Raghava N. Sriramaneni, Lakeesha Carmichael, Hans Loibner, Stephen D. Gillies, Alan J. Korman, Amy K. Erbe, Jacquelyn A. Hank, Alexander L. Rakhmilevich, Paul M. Harari, Paul M. Sondel	54
9	Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape 2017 ·Cancer Immunology Research ·Takuro Noguchi, Jeffrey P. Ward, Matthew M. Gubin, Cora D. Arthur, Sang Hun Lee, Jasreet Hundal, M. J. Selby, Robert F. Graziano, Elaine R. Mardis, Alan J. Korman, Robert D. Schreiber	242
10	CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8+ T Cell–Relevant Genes 2017 ·Cancer Immunology Research ·M. Ángela Aznar, Sara Labiano, Ángel Díaz‐Lagares, Carmen Molina, Saray Garasa, Arantza Azpilikueta, Iñaki Etxeberría, Alfonso R. Sánchez-Paulete, Alan J. Korman, Manel Esteller, Juan Sandoval, Ignacio Melero	35
11	Preliminary Results of A Phase I/IIA Study of BMS-986156 (GLUCOCORTICOID-Induced Tumour Necrosis Factor Receptor-Related Gene [GITR] AGONIST), Alone and In Combination with Nivolumab in Patients with Advanced Solid Tumours 2017 ·Asia-Pacific Journal of Clinical Oncology ·Lillian L. Siu, Neeltje Steeghs, Tarek Meniawy, Markus Joerger, Jennifer L. Spratlin, Sylvie Rottey, Adnan Nagrial, Adam Cooper, Roland Meier, Yun Shen, Penny Phillips, Gaurav Bajaj, Jochem Gokemeijer, Alan J. Korman, Kyaw Aung, Matteo S. Carlino	1
12	Agonistic CD40 mAb-Driven IL12 Reverses Resistance to Anti-PD1 in a T-cell–Rich Tumor 2016 ·Cancer Research ·Shin Foong Ngiow, Arabella Young, Stephen J. Blake, Geoffrey R. Hill, Hideo Yagita∥, Michele W.L. Teng, Alan J. Korman, Mark J. Smyth	72
13	In Situ Tumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine Treatments 2016 ·Cancer Research ·Zachary S. Morris, (unknown), David M. Francis, (unknown), Lauryn R. Werner, Lakeesha Carmichael, Richard K. Yang, Eric A. Armstrong, Shyhmin Huang, Fariba Navid, Stephen D. Gillies, Alan J. Korman, Jacquelyn A. Hank, Alexander L. Rakhmilevich, Paul M. Harari, Paul M. Sondel	119
14	Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab 2015 ·Cancer Research ·Yoshinobu Koguchi, Helena Hoen, Shelly Bambina, (unknown), (unknown), Brendan D. Curti, Walter J. Urba, Christina Milburn, Frances Rena Bahjat, Alan J. Korman, Keith S. Bahjat	39
15	Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2−/−IL2Rγnull Immunodeficient Mice 2015 ·Cancer Research ·Miguel F. Sanmamed, Inmaculada Rodríguez, Kurt A. Schalper, Carmen Oñate, Arantza Azpilikueta, María E. Rodríguez-Ruiz, Aizea Morales‐Kastresana, Sara Labiano, José Luis Perez‐Gracia, Salvador Martín‐Algarra, Carlos Alfaro, Guillermo Mazzolini, Francesca Sarno, Manuel Hidalgo, Alan J. Korman, Maria Jure–Kunkel, Ignacio Melero	129
16	In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates breakdown → 2014 ·Cancer Immunology Research ·Changyu Wang, Kent Thudium, Minhua Han, Xitao Wang, Haichun Huang, Diane Feingersh, Candy Garcia, Yi Wu, Michelle Kuhne, M. S. Srinivasan, Sujata Singh, Susan Wong, Neysa Garner, Heidi Leblanc, Roderick T. Bunch, Diann Blanset, Mark Selby, Alan J. Korman	472
17	Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells breakdown → 2013 ·Cancer Immunology Research ·M. J. Selby, John Engelhardt, Michael Quigley, Karla A. Henning, Tseng-hui Timothy Chen, M. S. Srinivasan, Alan J. Korman	670
18	PD-1/PD-L1 Interactions Contribute to Functional T-Cell Impairment in Patients Who Relapse with Cancer After Allogeneic Stem Cell Transplantation 2011 ·Cancer Research ·Wieger J. Norde, Frans Maas, Willemijn Hobo, Alan J. Korman, Michael Quigley, Michel G.D. Kester, Konnie M. Hebeda, J.H. Frederik Falkenburg, Nicolaas Schaap, Theo M. de Witte, Robbert van der Voort, Harry Dolstra	126
19	Anti–Programmed Death-1 Synergizes with Granulocyte Macrophage Colony-Stimulating Factor–Secreting Tumor Cell Immunotherapy Providing Therapeutic Benefit to Mice with Established Tumors 2009 ·Clinical Cancer Research ·Betty Li, Melinda VanRoey, Changyu Wang, Tseng-hui Timothy Chen, Alan J. Korman, Karin Jooss	153
20	Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies breakdown → 2009 ·The Journal of Experimental Medicine ·Karl S. Peggs, Sergio A. Quezada, Cynthia A. Chambers, Alan J. Korman, James P. Allison	726

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact